356 related articles for article (PubMed ID: 28720586)
1. A MALT lymphoma prognostic index.
Thieblemont C; Cascione L; Conconi A; Kiesewetter B; Raderer M; Gaidano G; Martelli M; Laszlo D; Coiffier B; Lopez Guillermo A; Torri V; Cavalli F; Johnson PW; Zucca E
Blood; 2017 Sep; 130(12):1409-1417. PubMed ID: 28720586
[TBL] [Abstract][Full Text] [Related]
2. Validation of the Marginal Zone Lymphoma International Prognostic Index.
Hong J; Cho J; Ko YH; Kim SJ; Kim WS
Ann Hematol; 2019 Feb; 98(2):457-464. PubMed ID: 30310985
[TBL] [Abstract][Full Text] [Related]
3. Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients.
Zhang T; Wu Y; Ju H; Meng J; Guo W; Ren G
Cancer Med; 2020 Jan; 9(1):194-203. PubMed ID: 31733094
[TBL] [Abstract][Full Text] [Related]
4. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
5. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
Kim HD; Cho H; Jeong H; Bang K; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Oh SY; Suh C
Br J Haematol; 2021 Apr; 193(2):307-315. PubMed ID: 33216979
[TBL] [Abstract][Full Text] [Related]
6. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma.
Alderuccio JP; Reis IM; Habermann TM; Link BK; Thieblemont C; Conconi A; Larson MC; Cascione L; Zhao W; Cerhan JR; Zucca E; Lossos IS
Am J Hematol; 2022 Dec; 97(12):1529-1537. PubMed ID: 36057138
[TBL] [Abstract][Full Text] [Related]
7. Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG).
Papaxoinis G; Fountzilas G; Rontogianni D; Dimopoulos MA; Pavlidis N; Tsatalas C; Pectasides D; Xiros N; Economopoulos T
Ann Oncol; 2008 Apr; 19(4):780-6. PubMed ID: 18156143
[TBL] [Abstract][Full Text] [Related]
8. Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41).
Jackson AE; Mian M; Kalpadakis C; Pangalis GA; Stathis A; Porro E; Conconi A; Cortelazzo S; Gaidano G; Lopez Guillermo A; Johnson PW; Martelli M; Martinelli G; Thieblemont C; McPhail ED; Copie-Bergman C; Pileri SA; Jack A; Campo E; Mazzucchelli L; Ristow K; Habermann TM; Cavalli F; Nowakowski GS; Zucca E
Oncologist; 2015 Oct; 20(10):1149-53. PubMed ID: 26268740
[TBL] [Abstract][Full Text] [Related]
9. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Zucca E; Conconi A; Martinelli G; Bouabdallah R; Tucci A; Vitolo U; Martelli M; Pettengell R; Salles G; Sebban C; Guillermo AL; Pinotti G; Devizzi L; Morschhauser F; Tilly H; Torri V; Hohaus S; Ferreri AJM; Zachée P; Bosly A; Haioun C; Stelitano C; Bellei M; Ponzoni M; Moreau A; Jack A; Campo E; Mazzucchelli L; Cavalli F; Johnson P; Thieblemont C
J Clin Oncol; 2017 Jun; 35(17):1905-1912. PubMed ID: 28355112
[TBL] [Abstract][Full Text] [Related]
10. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum immunoglobulin paraprotein in mucosa-associated lymphoid tissue (MALT) lymphoma.
Ren YM; Shang CY; Liang JH; Yin H; Xia Y; Wu JZ; Wang L; Jian-Yong L; Li Y; Xu W
Br J Haematol; 2022 Mar; 196(6):1353-1361. PubMed ID: 34961920
[TBL] [Abstract][Full Text] [Related]
12. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas].
He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W
Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094
[No Abstract] [Full Text] [Related]
13. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.
Zucca E; Conconi A; Pedrinis E; Cortelazzo S; Motta T; Gospodarowicz MK; Patterson BJ; Ferreri AJ; Ponzoni M; Devizzi L; Giardini R; Pinotti G; Capella C; Zinzani PL; Pileri S; López-Guillermo A; Campo E; Ambrosetti A; Baldini L; Cavalli F;
Blood; 2003 Apr; 101(7):2489-95. PubMed ID: 12456507
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of absolute monocyte count and lymphocyte to monocyte ratio in mucosa-associated lymphoid tissue (MALT) lymphoma.
Shang CY; Wu JZ; Ren YM; Liang JH; Yin H; Xia Y; Wang L; Li JY; Li Y; Xu W
Ann Hematol; 2023 Feb; 102(2):359-367. PubMed ID: 36624225
[TBL] [Abstract][Full Text] [Related]
15. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical characteristics and prognostic factors of gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma.
Xu X; Wang Z; Yu Y; Wang Y; Zhang L; Sun B; Da W; Zhang Y
J Gastroenterol Hepatol; 2014 Sep; 29(9):1678-84. PubMed ID: 24730769
[TBL] [Abstract][Full Text] [Related]
17. [The clinical characteristics and prognostic analysis of gastric mucosa-associated lymphoid tissue lymphoma of 103 cases].
Li XW; Xia B; Guo Q; Jin X; Yu Y; Zhao ZG; Wang XF; Wang YF; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):805-9. PubMed ID: 23384898
[TBL] [Abstract][Full Text] [Related]
18. Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.
Conconi A; Thieblemont C; Cascione L; Torri V; Kiesewetter B; Margiotta Casaluci G; Gaidano G; Raderer M; Cavalli F; Lopez Guillermo A; Johnson PW; Zucca E
Haematologica; 2020 Nov; 105(11):2592-2597. PubMed ID: 33131248
[TBL] [Abstract][Full Text] [Related]
19. Short survival and frequent transformation in extranodal marginal zone lymphoma with multiple mucosal sites presentation.
Alderuccio JP; Zhao W; Desai A; Ramdial J; Gallastegui N; Kimble E; de la Fuente MI; Husnain M; Rosenblatt JD; Alencar AJ; Schatz JH; Moskowitz CH; Chapman JR; Vega F; Reis IM; Lossos IS
Am J Hematol; 2019 May; 94(5):585-596. PubMed ID: 30784098
[TBL] [Abstract][Full Text] [Related]
20. The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas.
Tracy SI; Larson MC; Feldman AL; Maurer MJ; Novak AJ; Slager SL; Villasboas JC; Allmer C; Habermann TM; Farooq U; Syrbu S; Cerhan JR; Link BK
Am J Hematol; 2019 Jun; 94(6):658-666. PubMed ID: 30916801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
